<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387995</url>
  </required_header>
  <id_info>
    <org_study_id>LC2016ZD024</org_study_id>
    <nct_id>NCT03387995</nct_id>
  </id_info>
  <brief_title>Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics of Treatment of IA Using Stents</brief_title>
  <official_title>the Treatment of Intracranial Aneurysm Using Different Types of Stents Assisted Embolization :Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracranial aneurysms (IA) regarded the third cause of cerebral vascular disease is the
      majoy cause of subarachnoid hemorrhage (SAH). The mortality and morbidity account for 22% to
      25% in cerebrovascular disease. More than half of the ruptured IA survivors has serious nerve
      dysfunction such as hemiplegia, aphasia,which seriously harms to human health. Endovascular
      embolization is one of the main treatment ways of IA.However,there are no studies on the
      multicenter cases of stent selection strategy at home and abroad.Therefore, the investigators
      conduct a prospective study by comparing the clinical efficacy, follow-up results, and
      hemodynamics between preoperative and postoperative patients with different types of stent
      assisted embolization treatment of IA.The investigators also study the relationship between
      cyclin dependent kinase inhibitor 2B antisense RNA 1 gene（CDKN2BAS1 gene）of IA patients and
      the results, for making indication of stents, improving the cure rate, reducing the
      recurrence rate of IA patients, providing theory gist for interventional therapy of complex
      IA and simplying slection of stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies showed 3.6% - 6% for the incidence and 1% - 2% for the ruptctued rate of IA.The
      mortality and morbidity account for 22% to 25% in cerebrovascular disease ,which is a growing
      trend. IA is one of the major diseases which relate with people's living standards.
      Endovascular embolization is one of the main treatments of IA with less invasive, Better cure
      rates and higher safety. It has been developed rapidly and improve quality of patients' lives
      after treatmen.With the rapid development of neural intervention and the proliferation of
      specialized stents in IA, stent-assisted embolization technique is becoming more and more
      common .Especially, stents play an important role in intracranial aneurysmal aneurysm.

      There are many kinds intracranial stents for clinical surgery, but how to choose the
      appropriate stent type is one of the key issues that clinicians need to settle. And, there is
      no relevant multicenter cases study about selection strategy of intracranial stent at home
      and abroad.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The security evaluation of interventional therapy</measure>
    <time_frame>6 months later after operation</time_frame>
    <description>Modified Rankin score to measure the security of of interventional therapy</description>
  </primary_outcome>
  <other_outcome>
    <measure>The effectiveness evaluation of interventional treatment</measure>
    <time_frame>6 months later after operation</time_frame>
    <description>Raymond scale to measure the effectiveness of interventional treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>The hemodynamics of parent artery after interventional treatment</measure>
    <time_frame>1year later after operation</time_frame>
    <description>The curvature of parent artery will be measured by DSA or 3D-DSA</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the relationship between intracranial aneurysm and cyclin dependent kinase inhibitor 2B antisense RNA1（CDKN2BAS1）</measure>
    <time_frame>6 months later after operation</time_frame>
    <description>The investigators will take the participant's blood and the relationship between intracranial aneurysm and CDKN2BAS1 will be evaluated by ligase detection reaction-polymerase chain reaction(LDP-PCR)</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Treatment Outcome by Stent-assisted Embolization</condition>
  <arm_group>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <description>Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <description>Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <description>Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <description>Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
    <description>Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LVIS stent</intervention_name>
    <description>The group has 80 patients.</description>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solitire stent</intervention_name>
    <description>The group has 80 patients.</description>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Enterprise stent</intervention_name>
    <description>The group has 80 patients.</description>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neuroform stent</intervention_name>
    <description>The group has 80 patients.</description>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pipeline stent</intervention_name>
    <description>The group has 80 patients.</description>
    <arm_group_label>Anterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Middle cerebral artery aneurysm</arm_group_label>
    <arm_group_label>Posterior communicating artery aneurysm</arm_group_label>
    <arm_group_label>Internal carotid artery aneurysm</arm_group_label>
    <arm_group_label>Vertebrobasilar system aneurysms</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subject has intracranial aneurysms confirmed by CT arteriography (CTA) or magnetic
        resonance angiography (MRA) or digital subtraction angiography(DSA).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has intracranial aneurysms confirmed by CT arteriography (CTA) or magnetic
             resonance angiography (MRA) or digital subtraction angiography(DSA)

          -  Subject has accepted stent - assisted embolization treatment of intracranial aneurysm

        Exclusion Criteria:

          -  Subject has secondary intracranial aneurysms(e.g.traumatic aneurysm, infected
             aneurysm)

          -  Subject has received surgical clipping or endovascular treatment

          -  Subject has no intracranial aneurysms by DSA

          -  Subject has no aneurysm measurement

          -  Aneurysm of patients are not clear by imaging

          -  Subject cannot use stent because of the small parent artery

          -  Subject do not need to use stent because of narrow-neck aneurysm

          -  History of aneurysm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuanzhi Duan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, Zhujiang Hospital,Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZhuJiang Hospital,Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510282</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang X, Long XA, Luo B, Karuna T, Duan CZ. Factors responsible for poor outcome after intraprocedural rerupture of ruptured intracranial aneurysms: identification of risk factors, prevention and management on 18 cases. Eur J Radiol. 2012 Jan;81(1):e77-85. doi: 10.1016/j.ejrad.2011.02.015. Epub 2011 Feb 24.</citation>
    <PMID>21353424</PMID>
  </reference>
  <reference>
    <citation>Standhardt H, Boecher-Schwarz H, Gruber A, Benesch T, Knosp E, Bavinzski G. Endovascular treatment of unruptured intracranial aneurysms with Guglielmi detachable coils: short- and long-term results of a single-centre series. Stroke. 2008 Mar;39(3):899-904. doi: 10.1161/STROKEAHA.107.496372. Epub 2008 Feb 7.</citation>
    <PMID>18258836</PMID>
  </reference>
  <reference>
    <citation>Ishibashi T, Murayama Y, Urashima M, Saguchi T, Ebara M, Arakawa H, Irie K, Takao H, Abe T. Unruptured intracranial aneurysms: incidence of rupture and risk factors. Stroke. 2009 Jan;40(1):313-6. doi: 10.1161/STROKEAHA.108.521674. Epub 2008 Oct 9.</citation>
    <PMID>18845802</PMID>
  </reference>
  <reference>
    <citation>Gu DQ, Zhang X, Luo B, Long XA, Duan CZ. The effect of Neuroform stent-assisted coil embolization of wide-necked intracranial aneurysms and clinical factors on progressive aneurysm occlusion on angiographic follow-up. J Clin Neurosci. 2013 Feb;20(2):244-7. doi: 10.1016/j.jocn.2012.01.053. Epub 2012 Nov 30.</citation>
    <PMID>23201094</PMID>
  </reference>
  <reference>
    <citation>Ye HW, Liu YQ, Wang QJ, Zheng T, Cui XB, Gao YY, Lai LF, Zhang X, Li XF, Su SX, He XY, Duan CZ. Comparison between Solitaire™ AB and Enterprise stent-assisted coiling for intracranial aneurysms. Exp Ther Med. 2015 Jul;10(1):145-153. Epub 2015 May 8.</citation>
    <PMID>26170926</PMID>
  </reference>
  <reference>
    <citation>Li H, He XY, Li XF, Zhang X, Liu YC, Duan CZ. Treatment of giant/large internal carotid aneurysms: parent artery occlusion or stent-assisted coiling. Int J Neurosci. 2016;126(1):46-52. doi: 10.3109/00207454.2014.992427. Epub 2015 Jan 7.</citation>
    <PMID>25565057</PMID>
  </reference>
  <reference>
    <citation>Naggara ON, White PM, Guilbert F, Roy D, Weill A, Raymond J. Endovascular treatment of intracranial unruptured aneurysms: systematic review and meta-analysis of the literature on safety and efficacy. Radiology. 2010 Sep;256(3):887-97. doi: 10.1148/radiol.10091982. Epub 2010 Jul 15. Review.</citation>
    <PMID>20634431</PMID>
  </reference>
  <reference>
    <citation>Mitra D, Herwadkar A, Soh C, Gholkar A. Follow-up of intracranial aneurysms treated with matrix detachable coils: a single-center experience. AJNR Am J Neuroradiol. 2007 Feb;28(2):362-7.</citation>
    <PMID>17297013</PMID>
  </reference>
  <reference>
    <citation>Lopes D, Sani S. Histological postmortem study of an internal carotid artery aneurysm treated with the Neuroform stent. Neurosurgery. 2005 Feb;56(2):E416; discussion E416.</citation>
    <PMID>15670395</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment outcome</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>invertigators can share the original data 5 years after the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

